{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:26:47Z","timestamp":1784795207492,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.dld.2024.05.014","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T14:27:59Z","timestamp":1717856879000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1648-0348","authenticated-orcid":false,"given":"Julien","family":"Hoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-891X","authenticated-orcid":false,"given":"Adrien","family":"Grancher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-6448","authenticated-orcid":false,"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-0101","authenticated-orcid":false,"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bouhier-Leporrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Desgrippes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Miglianico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Avisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Baconnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Heng","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dutherage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-8525","authenticated-orcid":false,"given":"Karine Le","family":"Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gillibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dld.2024.05.014_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10","key":"10.1016\/j.dld.2024.05.014_bib0002","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","article-title":"Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"51","author":"Phelip","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"7\u20138","key":"10.1016\/j.dld.2024.05.014_bib0003","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bulcan.2018.11.016","article-title":"[Descriptive epidemiology of cancer in metropolitan France: incidence, survival and prevalence]","volume":"106","author":"Cowppli-Bony","year":"2019","journal-title":"Bull Cancer (Paris)"},{"issue":"17","key":"10.1016\/j.dld.2024.05.014_bib0004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.dld.2024.05.014_bib0005","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.dld.2024.05.014_bib0006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.dld.2024.05.014_bib0007","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2016.34.15_suppl.3512","article-title":"FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: a phase II randomized Study\u2014Prodige 14 \u2013 ACCORD 21 (METHEP-2), a unicancer GI trial","volume":"34","author":"Ychou","year":"2016","journal-title":"J Clin Oncol"},{"issue":"104","key":"10.1016\/j.dld.2024.05.014_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2018.09.006","article-title":"FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: results of the FFCD 1102 phase II trial","volume":"1990","author":"Bachet","year":"2018","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"12","key":"10.1016\/j.dld.2024.05.014_bib0009","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.dld.2024.05.014_bib0010","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.dld.2024.05.014_bib0011","first-page":"150","article-title":"Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer","volume":"24","author":"Blazevic","year":"2020","journal-title":"Contemp Oncol Poznan Pol"},{"key":"10.1016\/j.dld.2024.05.014_bib0012","series-title":"Cancer: principles and practice of oncology","first-page":"3120","year":"2004"},{"issue":"6","key":"10.1016\/j.dld.2024.05.014_bib0013","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/1097-0142(197112)28:6<1479::AID-CNCR2820280622>3.0.CO;2-M","article-title":"Kinetics of mammary tumor cell growth and implications for therapy","volume":"28","author":"Skipper","year":"1971","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.dld.2024.05.014_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.dld.2024.05.014_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","author":"Nielson","year":"2021","journal-title":"The Oncologist [Internet]"},{"key":"10.1016\/j.dld.2024.05.014_bib0016","article-title":"Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity","volume":"13","author":"Vary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.dld.2024.05.014_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12885-022-09831-7","article-title":"The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer","volume":"22","author":"Zainal Abidin","year":"2022","journal-title":"BMC Cancer"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T01:49:13Z","timestamp":1735782553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1590865824007722"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.05.014","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}